Table 1 Previous studies regarding cut-off values of the TG/HDL-C ratio.
Authors, year | Age of subjects (mean or range) | Country | Cut-off values | Units (#1) | Outcome | Ref. no |
|---|---|---|---|---|---|---|
McLaughlin et al. 2003 | 50 years (men and women with overweight) | USA | 3.0 (men and women) | mg/dl | Insulin resistance | [18] |
McLaughlin et al. 2005 | Mean years, 42–56 (men and women) | USA | 3.5 (men and women) | mg/dl | Insulin resistance | [4] |
Cordero et al. 2008 | 42–44 years (men and women) | Spain | 2.75 (men), 1.65 (women) | mg/dl | MS | [19] |
Li et al. 2008 | 20 years or older | USA | 3.0 (non-Hispanic whites and Mexican Americans); 2.0 (non-Hispanic blacks) (men and women) | mg/dl | Hyperinsulinemia | [20] |
Hadaegh et al. 2010 | 43.3 years (men); 40.8 years (women) | Iran | 4.7 (men), 3.7 (women) | mmol/L | Diabetes | [21] |
Kawamoto et al. 2010 | 60 years (non-obese men and women); 57 (overweight men and women) | Japan | 1.50 (non-obese men and women); 2.20 (overweight men and women) | mg/dl | Insulin resistance | [22] |
Summer et al. 2010 | 55 years (African-American men and women) | USA | 2.5 (men); indefinable (women) | mg/dl | Insulin resistance | [23] |
Arthur et al. 2012 | 44.23 years (postmenopausal women) | Ghana | 0.61 (women) | mmol/L | MS | [24] |
Salazar et al. 2012 | 46 years (men); 45 years (women) | Argentine | 3.5 (men); 2.5 (women) | mg/dl | Insulin resistance | [25] |
Liang et al. 2013 | 50 years or older (postmenopausal women) | China | 0.88 (women) | mmol/L | MS | [26] |
Chen et al. 2014 | 52.30 years (men, MS-); 51.98 years (men, MS+); 49.14 years (women, MS-); 58.58 years (women, MS+) | China | 1.6 (JIS criteria) and 1.2 (ATPIII criteria) (men); 1.1 (both criteria) (women) | mmol/L | MS | [27] |
Gasevic et al. 2014 | 46.8 years (men); 47.5 years (women) | Canada | 1.62 (men); 1.18 (women) | mmol/L | MS | [28] |
Unger et al. 2014 | 45 years (MS+); 33 years (MS-) | Argentine | 3.1 (men); 2.2 (women) | mg/dl | MS | [29] |
Zhang et al. 2015 | 52.6 years (men, normal weight); 52.2 (men, high weight); 49.8 years (women, normal weight); 54.9 years (women, high weight) | China | 1.51 (men); 0.84 (women) | mmol/L | Insulin resistance | [30] |
Chen et al. 2016 | 50.61 years (men, MS+); 48.70 (men, MS-); 53.54 (women MS+); 45.57 (women, MS-) | China | 1.10 (men); 0.90 (women) | mmol/L | MS | [31] |
Gharipour et al., 2016 | 50.7 (men and women) | Iran | 4.42 (men); 3.76 (women); 3.68 (men and women) | mg/dl | Ischemic heart disease and stroke (#2) | [32] |
Li et al. 2016 | Mean years: 49.44–53.99 (men); 48.65–56.71 (women) | China | men: 1.3 (HT), 1.3 (DL), 1.4 (DM), 1.4 (RFs); women: 0.9 (HT), 1.0 (DL), 1.0 (DM), 1.1 (RFs) | mmol/L | HT, DL, DM, RFs | [33] |
Paulmichl et al. 2016 | 43.9 years | Austria etc. | 2.05 (M value), 1.47 (M/I value) | mg/dl | Insulin resistance | [34] |
Song et al. 2016 | 54.40 years (diabetes); 41.12 years (non-diabetes) | China | 1.24 (men and women) | mmol/L | DM | [35] |
Abbasian et al. 2017 | 30–60 years | Iran | 4.03 (men); 2.86 (women) | mg/dl | MS | [36] |
Kang et al. 2017 | 9–13 years | Korea | 1.41 (men and women) | mg/dl | Insulin resistance | [37] |
Deng et al. 2018 | 68.5 years | China | 0.9 (men and women) | mmol/L | Acute ischemic stroke (#2) | [38] |